Compare CMPX & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPX | ESPR |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | 35 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 955.1M | 898.5M |
| IPO Year | N/A | 2013 |
| Metric | CMPX | ESPR |
|---|---|---|
| Price | $5.22 | $3.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $13.44 | $6.67 |
| AVG Volume (30 Days) | 1.8M | ★ 5.0M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $303,802,000.00 |
| Revenue This Year | N/A | $26.11 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $1.33 | $0.69 |
| 52 Week High | $5.86 | $4.13 |
| Indicator | CMPX | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 54.27 | 52.66 |
| Support Level | $4.83 | $3.66 |
| Resistance Level | $5.53 | $4.05 |
| Average True Range (ATR) | 0.26 | 0.18 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 62.77 | 29.00 |
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.